Our Editorial Team
Every peptide profile and blog post is reviewed by qualified professionals. Meet the team behind 50 Best Peptides.
Dr. Sarah Chen
Medical Reviewer
PharmD, BCPS — Board-Certified Pharmacotherapy Specialist
Dr. Chen brings 15 years of clinical pharmacy experience to 50 Best Peptides, having previously served as a clinical pharmacist at Johns Hopkins Medicine and an adjunct professor of pharmacology at the University of Maryland School of Pharmacy. She reviews every peptide profile for accuracy of mechanism-of-action descriptions, drug interaction warnings, and dosing protocol safety. Her research interests include peptide therapeutics and novel drug delivery systems.
James Mitchell
Editor-in-Chief
MSc Biochemistry, University of Edinburgh. 10 years in health science journalism.
James founded the editorial team at 50 Best Peptides after a decade covering pharmaceutical research and peptide therapeutics for peer-reviewed health publications. His background in biochemistry enables him to critically evaluate preclinical and clinical evidence, translating complex research into accessible, accurate content. He previously contributed to Healthline, Medical News Today, and the British Journal of Clinical Pharmacology's science communication initiative.
Dr. Elena Vasquez
Research Director
PhD Molecular Biology, Stanford University. Postdoctoral fellow, Salk Institute.
Dr. Vasquez oversees the evidence classification system at 50 Best Peptides, ensuring every claim is properly categorized by evidence level — from FDA-approved through clinical trials, animal studies, and anecdotal reports. Her doctoral research focused on growth factor signaling pathways and peptide-receptor interactions, giving her deep expertise in the mechanisms underlying peptide therapeutics.
Michael Okafor
Regulatory Affairs Analyst
JD, Georgetown University Law Center. Former FDA regulatory counsel.
Michael tracks the rapidly evolving regulatory landscape for peptide compounds across international jurisdictions. His legal background includes three years at the FDA's Center for Drug Evaluation and Research, where he worked on drug classification and compounding regulations. He provides the regulatory status updates on every peptide profile and monitors enforcement actions from the FDA, TGA, EMA, and WADA.
Dr. Priya Sharma
Clinical Research Reviewer
MBBS, MD (Pharmacology), AIIMS New Delhi. 8 years in clinical research.
Dr. Sharma evaluates the clinical trial evidence cited across all peptide profiles, assessing study design quality, sample sizes, and statistical significance. Her medical training at the All India Institute of Medical Sciences and subsequent career in clinical pharmacology research give her the expertise to distinguish robust evidence from preliminary findings — a distinction that is critical for reader safety in the peptide space.